Last reviewed · How we verify
LEO 32731 gastro-resistant capsule
LEO 32731 is a gastro-resistant capsule under development by LEO Pharma. It has completed Phase 1 trials assessing safety, tolerability, and pharmacokinetics in healthy volunteers. No FDA label is available, and further clinical data are needed.
At a glance
| Generic name | LEO 32731 gastro-resistant capsule |
|---|---|
| Sponsor | LEO Pharma |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LEO 32731 gastro-resistant capsule CI brief — competitive landscape report
- LEO 32731 gastro-resistant capsule updates RSS · CI watch RSS
- LEO Pharma portfolio CI